GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Q1 FY27 Results, ₹888 million Profit

RESULTS ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 03 Aug 2026, 06:12 PM IST  ·  BSE ID: d67dfedf-cef7-48d4-bb86-43a275c06945
View Original BSE Filing (PDF)
💡
In Simple Terms
The company announced its latest financial results and plans to lend money to its related businesses, totaling up to Rs. 650 Crores.
🤖 AI Summary
  • Board approved Q1 FY27 unaudited standalone and consolidated financial results for quarter ended June 30, 2026.
  • Approved advancing loans not exceeding Rs. 650 Crores to subsidiaries, associates, or group entities, subject to shareholder special resolution.
  • Approved a specific loan of up to ₹25 crore to KIMS Hospital Enterprises Private Limited, a material subsidiary.
  • Considered and approved DRAFT O&M Agreement and Call Option Agreement with Golden Lan Solutions and Sarwottam Healthcare.
  • Standalone Profit for the period was Rs. 688 million for Q1 FY27.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Q1 FY27)
Rs. 4,836 million
Not comparable — limited prior period data.
Profit for the period (Q1 FY27)
Rs. 688 million
Not comparable — limited prior period data.
Basic EPS (Q1 FY27)
Rs. 1.66
Not comparable — limited prior period data.
Approved Loan Limit to Group Entities
Rs. 650 Crores
Approved Loan to KIMS Hospital Enterprises Private Limited
₹25 crore
🏢 How This Affects the Company
💰
Financial Impact
The approval to advance loans up to Rs. 650 Crores to group entities could impact the company's cash flow and inter-company financing structures. The specific loan of up to ₹25 crore to a material subsidiary directly affects capital allocation.
⚠️
Risk Impact
Shareholder approval for the Rs. 650 Crores loan facility is a key regulatory step, and its outcome will determine the full extent of this financial commitment.
👥 What This Means For Shareholders
✅
Action Required
Shareholders will need to vote on the special resolution for advancing loans not exceeding Rs. 650 Crores to subsidiaries/associates in the ensuing General Meeting.
👤
Who Is Affected
All shareholders will be affected by the decision to advance loans up to Rs. 650 Crores to group entities, as it concerns the allocation of company funds. The specific loan to KIMS Hospital Enterprises Private Limited also affects capital deployment.
🔍
Management Signal
The management is signaling an intent to support growth and operational needs within its group entities through significant inter-company lending and exploring new operational agreements.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Outcome of the shareholder meeting regarding the Rs. 650 Crores loan approval.
Execution details of the O&M and Call Option Agreements with Golden Lan Solutions and Sarwottam Healthcare.
Consolidated financial results for Q1 FY27 once released to understand group performance.
MEDIUM RISK Significant inter-company loan approvals, especially the Rs. 650 Crores subject to shareholder vote, introduce financial and governance risks.
💡 Investor Takeaway
Krishna Institute of Medical Sciences reported a standalone profit of Rs. 688 million and revenue of Rs. 4,836 million for Q1 FY27. The board approved advancing loans up to Rs. 650 Crores to group entities, subject to shareholder approval, and a ₹25 crore loan to a material subsidiary.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone Profit for the period increased to Rs. 688 million in Q1 FY27 from Rs. 607 million in the previous quarter ended March 31, 2026.
  • Revenue from operations increased to Rs. 4,836 million in Q1 FY27 from Rs. 4,562 million in the previous quarter.

⚠️ Concerns

  • The significant loan approval of Rs. 650 Crores to subsidiaries/associates requires shareholder special resolution, introducing a dependency for implementation.
  • Total expenses for the quarter ended June 30, 2026, were Rs. 3,948 million, higher than Rs. 3,780 million in the previous quarter.
❓ Frequently Asked Questions
What was Krishna Institute of Medical Sciences' standalone profit for the quarter ended June 30, 2026?
Krishna Institute of Medical Sciences reported a standalone profit of Rs. 688 million for the quarter ended June 30, 2026.
What was Krishna Institute of Medical Sciences' revenue from operations for Q1 FY27?
The revenue from operations for Krishna Institute of Medical Sciences for the quarter ended June 30, 2026, was Rs. 4,836 million.
What loan amount did Krishna Institute of Medical Sciences approve for its group entities?
Krishna Institute of Medical Sciences approved advancing loans not exceeding Rs. 650 Crores to any subsidiaries, associates, or group entities, subject to shareholder approval.
Was a specific loan approved for a subsidiary of Krishna Institute of Medical Sciences?
Yes, the Board approved a specific loan of up to ₹25 crore to KIMS Hospital Enterprises Private Limited, a material subsidiary.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.